Is pretreatment PSA velocity associated with prostate-cancer-specific mortality rate after radiotherapy?

Nature Clinical Practice Urology

Volumn 3, Issue 1, 2006, Pages 12-13

  Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Prognosis; Prostate cancer; PSA velocity; Radiotherapy; Risk assessment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BIOCHEMISTRY; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; RISK ASSESSMENT; SHORT SURVEY; TREATMENT FAILURE; VELOCITY;

EID: 31844432264     PISSN: 17434270     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpuro0399     Document Type: Short Survey

References (5)

1. Roach M 3rd et al. (2003) Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology 61: 730-735
2. D'Amico AV et al. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125-135
3. Coen JJ et al. (2002) Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 20: 3199-3205
4. Hanks GE et al. (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21: 3972-3978
5. Jacob R et al. (2004) The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 100: 538-543